Context:
A client in the botanical extracts industry requested an Ames test to assess the mutagenicity of a plant extract used in their formulation. The test returned a positive result, flagging potential genotoxicity—a major concern for regulatory approval and marketability.
GenEvolutioN’s Approach:
Rather than stopping at the initial positive result, the GenEvolutioN team undertook a detailed chromatographic analysis to fractionate the extract and isolate the compound(s) responsible for the mutagenic response. By leveraging advanced analytical techniques (including HPLC and molecular identification), the exact molecule triggering the positive Ames result was identified.
Results & Impact:
GenEvolutioN’s investigation revealed that the active compound—while positive in the Ames test—was a naturally occurring component of the plant with no known mutagenic effect in humans. This distinction was critical: the compound’s reactivity in vitro did not translate to a real mutagenic risk for end users.
By going beyond the routine test protocol and providing in-depth molecular analysis, GenEvolutioN enabled the client to:
- Refine their safety documentation for regulators and stakeholders.
- Avoid unnecessary reformulation or withdrawal of their product.
- Demonstrate a proactive, evidence-based approach to product safety.
Key takeaway:
This case exemplifies GenEvolutioN’s role as a scientific partner, not just a testing provider—helping clients transform regulatory challenges into clear, actionable insights. Our ability to interpret ambiguous in vitro results (e.g., distinguishing between actual mutagenicity and test artifacts) is a core asset for clients in botanical, cosmetic, and food industries.
Looking ahead: GenEvolutioN continues to advance mutagenicity assessment, with innovative in vitro solutions like the Nano Ames and MC Nano Ames tests for complex matrices and nanoparticle-containing samples.
